#VisualAbstract: Ipilimumab plus anti-PD-1 therapy is effective in patients with anti-PD-L1 resistant metastatic melanoma
Click to read the study in The Lancet Oncology.
Tag: anti-PD-1
#VisualAbstract: Prolgolimab is efficacious and tolerable in patients with advanced melanoma
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Adjuvant pembrolizumab does not reduce health-related quality of life in patients with stage III melanoma
Click to read the study in The Lancet Oncology. Click to see previously reported survival outcomes from the same cohort.
#VisualAbstract: Pembrolizumab improves long-term survival in patients with stage III melanoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)
Click to read the study in Melanoma Research.
#VisualAbstract: BRAF/MEK inhibitor therapy may be associated with risk of uveitis in patients with advanced melanoma
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Prognosis for advanced melanoma has improved between 2013 to 2017 for patients in the Netherlands
Click to read the study in the European Journal of Cancer.